Kausch I, Böhle A
Department of Urology, Research Center Borstel, Medical University of Lübeck, Germany.
Eur Urol. 2002 Jan;41(1):15-29. doi: 10.1016/s0302-2838(01)00007-0.
The current pathological and clinical parameters provide important prognostic information, yet still have limited ability to predict the true malignant potential of most bladder tumors. In the last years, investigation of the basic mechanisms involved in carcinogenesis and tumor progression by molecular biology has provided a host of markers which are of potential diagnostic or prognostic value for bladder carcinoma. These markers may serve as tools for early and accurate prediction of tumor recurrence, progression and development of metastases and for prediction of response to therapy. The precise prediction of tumor biological behavior would facilitate treatment selection for patients who may benefit from radical surgical treatment or adjuvant therapy. We provide a current, comprehensive review of the literature on bladder tumor markers with a special emphasis on their prognostic potential. The literature suggests that currently no single marker is able to accurately predict the clinical course of bladder tumors and thus would serve as a reliable prognosticator. A combination of prognostic markers could predict which superficial tumors need an aggressive form of therapy and which invasive tumors require adjuvant therapy. Altogether, the most promising markers are, at this point, Ki-67 and p53 expression as well as matrixmetalloproteinase complex and angiogenesis.
目前的病理和临床参数提供了重要的预后信息,但在预测大多数膀胱肿瘤的真正恶性潜能方面能力仍然有限。在过去几年中,通过分子生物学对致癌作用和肿瘤进展所涉及的基本机制进行的研究提供了许多对膀胱癌具有潜在诊断或预后价值的标志物。这些标志物可作为早期准确预测肿瘤复发、进展和转移发生以及预测治疗反应的工具。对肿瘤生物学行为的精确预测将有助于为可能从根治性手术治疗或辅助治疗中获益的患者选择治疗方案。我们对膀胱肿瘤标志物的文献进行了全面的最新综述,特别强调了它们的预后潜力。文献表明,目前没有单一标志物能够准确预测膀胱肿瘤的临床进程,因此不能作为可靠的预后指标。多种预后标志物联合使用可以预测哪些浅表肿瘤需要积极的治疗方式,哪些浸润性肿瘤需要辅助治疗。总之,目前最有前景的标志物是Ki-67和p53表达以及基质金属蛋白酶复合物和血管生成。